CAR-T THERAPY FOR
SOLID TUMORS
China runs more than 60% of global solid tumor CAR-T trials — producing the worlds first published responses in lung, liver, gastric, ovarian, and brain cancers. All programmes are Phase I/II investigational; trial drug cost is covered by sponsors.
analyticsAt a Glance
- check_circleExpanding beyond blood cancers to lung, colon, breast, and gastric tumours
- check_circleTargets HER2, MSLN, EGFRvIII, MUC1, and other solid tumour antigens
- check_circleTumour microenvironment penetration remains the key research challenge
- check_circleMultiple early-phase trials active in China, the US, and Europe
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Ready to Explore Solid Tumor CAR-T Therapy in China?
CancerFax connects international patients with Chinas leading solid tumor CAR-T programmes — targeting GD2, EGFR, HER2, mesothelin, GPC3, AFP, CLDN18.2, and more across lung, liver, gastric, ovarian, glioblastoma, and other major cancer types. Trial drug cost: USD 0 for eligible patients.
All solid tumor CAR-T programmes described are investigational (Phase I or II) and have not received regulatory approval. This content is for informational purposes only and does not constitute medical advice. Consult a qualified oncologist before making treatment decisions.